Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RY109
- Development stage
- Preclinical
- Lead developer
- Reyon Pharmaceutical
- Modality
- Prophylactic Vaccines → Vaccines & Immunotherapeutics, DNA Vaccines → Plasmid DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
RY109 is a plasmid DNA (pDNA)-based therapeutic vaccine being developed by Reyon Pharm for the treatment of ovarian cancer. As a therapeutic vaccine, it is designed to stimulate the patient's immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. The drug utilizes a DNA plasmid platform to deliver genetic material into host cells, which then express the target antigens to induce a specific T-cell mediated immune response. RY109 is currently in the preclinical stage of development as part of Reyon Pharm's oncology pipeline.
Beyond the preview
Go deeper on RY109.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RY109.